Naproxeno Aurovitas (Naproxen)

Naproxen works by blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. By lowering prostaglandin levels, the drug reduces the sensitisation of pain receptors, diminishes inflammation, and helps lower body temperature during febrile episodes.

The appropriate dose of Naproxeno Aurovitas is determined by the prescribing clinician based on the patient’s specific condition, severity of symptoms, age, renal and hepatic function, and any concomitant medications. Dosage regimens are individualized and should not be altered without medical advice.

Safety data for naproxen in pregnancy and lactation are limited. It is generally avoided in the third trimester because of potential fetal cardiovascular effects, and caution is advised during the first two trimesters. Breastfeeding mothers should consult their physician, as naproxen can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Naproxeno Aurovitas. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both naproxen and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Naproxen has a longer half‑life, allowing twice‑daily dosing, whereas ibuprofen often requires three‑ to four‑times‑daily administration. Individual patient response, gastrointestinal tolerance and specific risk profiles guide the choice between them.

Naproxeno Aurovitas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually with a full glass of water. It may be taken with food or milk to lessen gastrointestinal discomfort, but it should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include gastrointestinal bleeding or ulceration, severe renal impairment, and increased risk of cardiovascular events such as heart attack or stroke. Patients should be educated to seek immediate medical attention if they experience black stools, sudden severe abdominal pain, swelling, or unexplained shortness of breath.

Naproxeno Aurovitas is contraindicated in individuals with known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, and those who have experienced a recent coronary artery bypass graft. Caution is also advised for patients with impaired renal or hepatic function.